Managing the Diabetes Burden: Powerful Growth Drivers Reshaping the Saudi Diabetes Care Market

Within devices, market structure highlights why monitoring is a priority. Mordor Intelligence states that monitoring devices captured 61.35% of Saudi Arabia’s diabetes devices market share in 2025, while continuous glucose monitoring (CGM) systems are projected to grow at a 5.32% CAGR through 2031. Patient mix also shapes demand: type 2 diabetes users accounted for 83.60% of total device volume in 2025, while type 1 diabetes is expected to grow at a 4.55% CAGR to 2031. Care location is another core driver. Homecare dominated with a 54.40% market share in 2025, and retail pharmacies held a 61.20% share that year—signals that access and self-management are central to ongoing device uptake.

Digital Diabetes Management Is Scaling Through CGM, Wearables, and Remote Care

Digital platforms are expanding the tools available for self-management and clinician oversight. Mobility Foresights notes that Saudi Arabia’s digital diabetes market is expanding rapidly due to rising diabetes prevalence and increased adoption of digital health technologies, with CGM, insulin delivery systems, and mobile health apps driving transformation. It also highlights AI-powered analytics, telemedicine, and remote patient monitoring as accelerators, supported by healthcare reforms, digital health investments, and improved connectivity and smartphone penetration. In market sizing, Mobility Foresights projects the Saudi Arabia Digital Diabetes Market to reach USD 42.7 billion by 2031 from USD 17.9 billion in 2025 (15.6% CAGR), emphasizing remote monitoring and telehealth-driven engagement between patients and providers.

Segment shares reinforce the direction of travel in digital management. Precedence Research estimates the Saudi Arabia digital diabetes management market at USD 136.17 million in 2025 and forecasts it to reach nearly USD 322.36 billion by 2035, expanding at a 9% CAGR from 2026 to 2035, citing rising diabetes prevalence and digital health initiatives. In its 2025 product split, CGM systems hold the largest share at 39%, followed by smart glucose meters (18%), smart insulin pumps/closed-loop systems (17%), and smart insulin pens (14%). By type, wearable devices dominate with a 58% share versus 42% for hand-held devices. By end use, home settings lead with a 65% share, while hospitals account for 28%.

Policy, reimbursement, and ecosystem partnerships are also shaping adoption, while cost and regulation influence pace. Mordor Intelligence links Vision 2030 to domestic manufacturing, digital health adoption, and preventive care, and notes a measurable increase in approvals for CGM reimbursement. Mobility Foresights adds that expansion of reimbursement policies for digital therapeutics and monitoring devices supports long-term growth, alongside rising awareness of preventive care and lifestyle tracking. At the same time, Mobility Foresights flags high costs for advanced devices such as CGMs and insulin pumps, plus reimbursement gaps that can increase out-of-pocket spending. Regulatory tightening can lengthen timelines, but Mordor Intelligence argues stricter Saudi Food and Drug Authority (SFDA) rules reduce counterfeit risk and strengthen clinician confidence, supporting broader diffusion of advanced systems over time.